Diabetes medicines show an observational link with dementia risk
A review linked starting SGLT2 inhibitors with less newly diagnosed dementia than starting DPP-4 inhibitors; whether the medicines caused that difference remains uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Starting SGLT2 inhibitors was associated with a lower rate of dementia than starting DPP-4 inhibitors among people with type 2 diabetes. Similar associations appeared for Alzheimer's disease and vascular dementia. These studies used existing records, so they cannot establish that the medicines prevented dementia or justify switching medication.
This abstract-based summary lacks follow-up lengths and absolute dementia rates. Differences between medicine users could contribute to the association despite statistical adjustment.
What researchers found
New dementia of any cause
SGLT2 versus DPP-4 starters; follow-up length unreported. The estimated rate of developing dementia at a given time was 0.74 times the comparator's, with an uncertainty range of 0.62–0.87 times. This gives neither an absolute probability nor proof of prevention.
What adjustment can establish
The review combined estimates adjusted for differences between groups. These were observational comparisons drawn from existing records, so adjustment cannot establish that the medicines themselves caused the dementia pattern.
Individual medicines remain uncertain
Separate analyses of individual medicines produced different statistical significance results. That does not establish that one medicine outperforms another, because a direct comparison is needed to answer that question.
The original publication
Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP-4 Inhibitors: A Systematic Review and Meta-Analysis.
Kumari K, Bai A, Geeta F et al.
Endocrinol Diabetes Metab · 2026
- PubMed ID
- 41777041
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.